Revenue during the quarter grew 12.91 percent to $2.36 million from $2.09 million in the previous year period.

Operating loss for the quarter was $10.76 million, compared with an operating loss of $13.25 million in the previous year period.

"We are pleased with the progress we’ve made in advancing our pipeline in 2016. For CUDC-907 and CA-170, we remain focused on patient enrollment in their respective trials to assess their benefit in cancer patients. The Phase 1 trial for CA-170 continues to progress on track through the dose escalation stage, and based on the early data, we have recently received regulatory approval to begin extension of the CA-170 Phase 1 study and enroll immunotherapy-naïve patients in Korea and Spain, with additional trial centers in other European countries projected to open in the second quarter. The Phase 2 trial of CUDC-907 in patients with relapsed/refractory MYC-altered diffuse large B cell lymphoma, or DLBCL is nearing completion of patient enrollment, and our goal is to assess CUDC-907's efficacy in this patient population, as measured by the overall response rate in up to 60 patients. Depending on the Phase 2 trial results, we expect to hold discussions with the FDA regarding potential for accelerated approval of CUDC-907 as a monotherapy in this setting. In addition, we are completing IND-enabling studies of CA-327 and CA-4948,” said Ali Fattaey, Ph.D., Curis's chief executive officer."

Debt comes down
Curis, Inc. has recorded a decline in total debt over the last one year. It stood at $19.86 million as on Dec. 31, 2016, down 17.82 percent or $4.30 million from $24.16 million on Dec. 31, 2015. Total debt was 34.39 percent of total assets as on Dec. 31, 2016, compared with 25.45 percent on Dec. 31, 2015. Debt to equity ratio was at 0.68 as on Dec. 31, 2016, up from 0.37 as on Dec. 31, 2015.